Home Tags ESMO

Tag: ESMO

ESMO 2020: In Heavily-pretreated Metastatic Urothelial Cancer Sacituzumab Govitecan Shows 27%...

Heavily-pretreated, cisplatin-eligible, patients benefit from treatment with sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy®; Immunomedics).This is the conclusion from an analysis of data from the pivotal...

ESMO 2020: Updated Interim Data of XMT-1536 Supports Continued Development in...

Updated interim phase I date for the safety, tolerability, and efficacy porting for the ovarian cancer cohort of an ongoing expansion study evaluating XMT-1536...

ESMO 2020: XMT-1536 Shows 34% ORR in Phase I Expansion Study...

Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase I study evaluating XMT-1536...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2020: Late-Breaking Data for HER3 Directed ADC Patritumab Deruxtecan in...

Data for patritumab deruxtecan (U3-1402; Daiichi Sankyo) and fam-trastuzumab deruxtecan-nxki* (Enhertu®; Daiichi Sankyo/AstraZeneca), two antibody-drug conjugates (ADC) based on Daiichi Sankyo's proprietary DXd ADC...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

FORWARD II Triplet Combination Demonstrates Encouraging Anti-tumor Activity

Safety and overall response data from the Phase Ib FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with carboplatin and bevacizumab (Avastin®; Genentech/Roche)...

Encouraging Data for Novel ADC Presented at ESMO 2016

During the annual meeting of the European Society for Medical Oncology (ESMO) being held October 7 – 11, 2016 in Copenhagen, Denmark, preliminary data for PF-06647020...

Promising Phase I Data for Enfortumab Vedotin (ASG-22ME) and ASG-15ME in...

The annual congress of the European Society of Medical Oncology (ESMO), this year held in Copenhagen, Denmark (October 7 - 11, 2016) is the premier...

Initial Results from Phase I Trial with anti-HER2 ADC SYD985 Shows...

Researchers working for Dutch pharmaceutical company Synthon Biopharmaceuticals based in Nijmegen, The Netherlands, report positive initial results from the dose-escalation part of its ongoing first-in-human trial...

How to Design Clinical Trials in the Era of Targeted Therapies

Antibody–drug conjugates or ADCs are a burgeoning class of targeted therapies designed to deliver dual therapies in a single, cancer cell-killing package. Targeted therapies...
ESMO 2014 Congress - Madrid, Spain

Improved Survival in Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated with...

Interim results from the phase IIb TARGET Trial, presented as Late-Breaking News at the annual meeting of the European Society for Medical Oncology (ESMO), being held September 26 - 30, 2014 in Madrid, Spain, shows improved survival in adenocarcinoma non-small cell lung cancer patients treated the small molecule drug conjugate (SMDC) vintafolide, being developed byEndocyte, in combination with docetaxel (Taxotere®; Sanofi).[1]